← All trials
NCT04781387
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 5, 2021
- Primary completion
- Dec 28, 2022
- Completion date
- Feb 21, 2023
- First posted
- Mar 4, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 108
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Crestone, IncLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Crestone, IncOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.